Irreversible electroporation (IRE) : A  minimally invasive therapeutic option in prostate cancer.

[Irreversible electroporation (IRE) : A minimally invasive therapeutic option in prostate cancer]. Radiologe. 2017 May 05;: Authors: Wiggermann P, Brünn K, Bäumler W Abstract CLINICAL PROBLEM: Prostate cancer is one of the most common malignant diseases in older men. As such, screening and early detection are of crucial importance. STANDARD TREATMENT: The standard management of prostate cancer includes radical prostatectomy, radiation therapy, or hormonal therapy. These standard therapies yield excellent oncologic results, but also produce significant side effects. In cases of low-risk prostate cancer, these therapies might result in over-treatment; for this reason, active surveillance has been introduced. However, acceptance of this strategy varies between patients. TREATMENT INNOVATIONS: Irreversible electroporation is a novel non-thermal ablation technique for soft tissues. The ablation mechanism of irreversible electroporation has some theoretical advantages in the treatment of prostate cancer. It allows image-guided focal treatment of malignant prostate tissue and a potential sparing of adjacent structures, thereby theoretically resulting in a marked reduction in treatment-related side effects compared with standard management. PRACTICAL RECOMMENDATIONS: Although irreversible electroporation is a promising ablation technique, it should only be used in the context of clinical trials to treat pros...
Source: Der Radiologe - Category: Radiology Authors: Tags: Radiologe Source Type: research

Related Links:

CONCLUSIONS: Luteinizing hormone-releasing hormon antagonists may reduce acute urinary tract toxicity during prostate cancer external beam radiotherapy compared with luteinizing hormone-releasing hormon agonists, in particular in patients with moderate to severe symptoms at the start of treatment. PMID: 32875317 [PubMed - as supplied by publisher]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Jpn J Clin Oncol Source Type: research
ConclusionOur survey established the prescription attitude of ADT and new hormonal agents (abiraterone, enzalutamide, apalutamide) by Italian Radiation Oncologists and highlighted the importance of expertise in global PC management.
Source: La Radiologia Medica - Category: Radiology Source Type: research
(Brigham and Women's Hospital) A new study by investigators from Brigham and Women's Hospital found that for men with unfavorable intermediate-risk or high-risk localized prostate cancer, who are receiving radiation and hormone therapy, delaying radiation while remaining on hormone therapy is unlikely to impact survival.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Conclusion: No difference in the toxicity profile could be identified between hypofractionation and conventional fractionation. Our schedule of 2,25Gy/fr seems safe and tolerable by the patients with acceptable rates of acute and late toxicity.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
AbstractTo evaluate the outcomes of total eradication therapy (TET), designed to eradicate all sites of visible cancer and micrometastases, in men with newly diagnosed oligometastatic prostate cancer (OMPCa). Men with ≤ 5 sites of metastases were enrolled in a prospective registry study, underwent neoadjuvant chemohormonal therapy, followed by radical prostatectomy, adjuvant radiation (RT) to prostate bed/pelvis, stereotactic body radiation therapy (SBRT) to oligometastases, and adjuvant hormonal therapy (HT) . When possible, the prostate-specific membrane antigen targeted18F-DCFPyL PET/CT (18F-DCFPyL) scan was o...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th. ERLEADA® i...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
CONCLUSION: Combined RT + HT treatment was associated with temporary lower scores in sexual and hormonal HRQoL compared with RT only. Intermediate- and high-risk CaP patients should be counseled about the possible declines in HRQoL associated with HT. PMID: 32139288 [PubMed - as supplied by publisher]
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
Conclusions: RT, despite modern techniques, affects the sexual function of PCa patients in varying degrees. Reducing radiation doses to penile structures may play a role in preventing erectile dysfunction.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Abstract Cancer of the prostate are cancers in which most incidences are slow growing and in the U.S., a record of 1.2 million new cases of prostate cancer occurred in 2018. The rates of this type of cancer have been increasing in the developing nations. The risk factors for prostate cancer include age, family history, and obesity. It is believed that the rate of prostate cancer is correlated with the Western diet. Various advances in methods of radiotherapy have contributed to lowering morbidity. Therapy for hormone-refractory prostate cancer is making progress, for almost all men with metastases will proceed to ...
Source: Current Topics in Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Top Med Chem Source Type: research
Thousands of men across the world have participated in randomized clinical trials testing the role of hormone therapy in the curative treatment of localized, high-risk prostate cancer. Over several decades, we have established that long-term hormone therapy improves survival, even in the setting of dose-escalated external beam radiation therapy (EBRT).1 Recently reported clinical trials suggest that for some men 18 months of hormone therapy may be a suitable duration that balances treatment efficacy with quality-of-life preservation.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Editorial Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Hormonal Therapy | Hormones | Prostate Cancer | Radiation Therapy | Radiology